Jan 5 2010
Hiru Corporation www.hirucorporation.com welcomes the integration of its MindUp Cancer Project www.mindupbioresearch.com into the HIRU corporation (HIRU; www.hirucorporation.com). This asset was recently acquired on a cash and stock basis as reported previously.
Dr. Sabera Ruzdijic the project and team manager of the MindUp cancer project points out that this integration brings major advantages to all the partners. In this way, HIRU is establishing its position in the biotech market, while the MindUp Cancer Project upgrades from the basic research to the commercial level.
Dr. Ruzdijic added: "Also, as a part of HIRU corporation we will be able to test the potency of herbal extracts and herbal preparations on our human cancer cell lines. Just to remind, MindUp BioResearch group is working on establishment of resistant cancer human cell lines with intention to examine new therapeutic modalities in overcoming resistance to standard chemotherapy in the area of cancer treatment. In addition, we perform the measurement of the frequency of gene mutations and chromosomal aberrations (frequency of genomic instability) in genomes of patients with non-small cell lung cancer (NSCLC). In course of this research ten genes altered during NSCLC promotion and progression are identified. These genes may be potential biomarkers and useful for target therapy, as well as for testing and finding new therapies. Target therapy enables the application of personalized treatment, which again could improve the patient survival."
Furthermore, it will allow the medical team of MindUp to offer non competitive consulting services back to HTDS (company it acquired Mind Up from) and other interested parties for the limited scope of stem cell bank and rejuvenate medical procedures project(s).
SOURCE Hiru Corporation
Two analgesic drugs may one day be repurposed as anti-tumor therapies